GlassScriptPhysician profile
Brian Andrew Farah
NPI 1174552079
$605,063.08
in general payments reported to CMS, 2019-2025
13 companies · $141K in 2025
The $141K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $85K · 2020: $30K · 2021: $97K · 2022: $97K · 2023: $86K · 2024: $70K · 2025: $141K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $251K · Travel and Lodging: $23K · Consulting Fee: $16K · Food and Beverage: $7,533.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $250,702.63 |
| Travel and Lodging | $22,698.00 |
| Consulting Fee | $15,628.00 |
| Food and Beverage | $7,533.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $198,139.24 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Nuedexta |
| Neurocrine Biosciences, INC. | $153,036.20 | 2019-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $118,470.18 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $81,911.55 | 2019-2025 | Aristada, Aristada Initio, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $28,600.82 | 2021-2025 | Uzedy, Austedo |
| Idorsia Pharmaceuticals US INC | $21,319.83 | 2022-2023 | Quviviq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,640.53 | 2020-2024 | Caplyta |
| Janssen Pharmaceuticals, INC | $432.59 | 2019-2023 | Invega Sustenna, Invega Trinza |
| Lundbeck LLC | $344.24 | 2021-2025 | Abilify Maintena |
| Axsome Therapeutics, INC. | $69.25 | 2023 | Auvelity |
| Janssen Scientific Affairs, LLC | $68.86 | 2019 | |
| Ironshore Pharmaceuticals INC. | $16.91 | 2019 | |
| Indivior INC. | $12.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Farah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.